CTOs on the Move


 
We created the first FDA-cleared app-enabled thermometer because, from our work in the health systems within the U.S. and across impoverished nations throughout the world, we`ve learned that an elevated temperature is often the first sign of sickness. By building intelligence into a once basic thermometer and turning it into a connected device, we`re able to keep an eye on illnesses from beginning to end. We can more quickly alert users when fever and symptoms warrant closer monitoring or a visit to the doctor. Our network of connected thermometers can even offer helpful insights such as common illnesses that may be ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kinsahealth.com
  • 535 Mission St 18th Floor
    San Francisco, CA USA 94105
  • Phone: 415.236.4811

Executives

Name Title Contact Details

Funding

Kinsa raised $17M on 03/08/2017

Similar Companies

Vertiflex

Vertiflex is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in San Clemente, CA. To find more information about Vertiflex, please visit www.vertiflex.net

American Red Cross - St. Paul Area

American Red Cross - St. Paul Area is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Timicoin

The most reliable, completely - decentralized, health information exchange is waiting for you.

DR Management

DR Management is a Fort Wayne, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nivalis Therapeutics

Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.